Clinical trial data review on weight-loss drugs reveals weight regain patterns post-medication discontinuation, impacting weight management strategies.

For adults with type 2 diabetes and obesity, glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a ...

Baseline BMI may play a significant role in improving exercise capacity, body weight and BP among patients with HF with ...

Explore how semaglutide and tirzepatide may protect against dementia and stroke—keep reading for clinical implications and evidence.

Drugs like Ozempic and Mounjaro are becoming increasingly popular for treating obesity and type 2 diabetes. These medications ...

It isn't easy finding high-yield dividend growth stocks when the market is at an all-time high. Shares of Novo Nordisk and ...

India is emerging as a key player in the global weight management industry, driven by a rising obesity crisis and the impending patent expirations of blockbuster drugs. Pharmaceutical giants are ...

While many believe the agents to be potential game changers, evidence is still lacking in psoriatic disease, and experts urge ...

Weight-loss drugs like semaglutide and tirzepatide may help shrink waistlines, but new research shows they fail to boost ...

Patients put on weight loss drugs like Ozempic and Wegovy may start regaining weight within weeks of discontinuing them, a ...

Patients prescribed drugs to help them lose weight may experience a rebound in weight gain after halting their prescription, ...

GLP-1 drugs like Ozempic and Mounjaro helped men with low testosterone raise their levels without hormone replacement in a ...